## Lihua Qiu

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8968768/publications.pdf

Version: 2024-02-01

		516710	552781
28	890	16	26
papers	citations	h-index	g-index
30	30	30	1434
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Cisplatin–alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells. Biomaterials, 2014, 35, 4297-4309.	11.4	101
2	MicroRNA-7 Inhibits Tumor Metastasis and Reverses Epithelial-Mesenchymal Transition through AKT/ERK1/2 Inactivation by Targeting EGFR in Epithelial Ovarian Cancer. PLoS ONE, 2014, 9, e96718.	2.5	84
3	TWEAK-stimulated macrophages inhibit metastasis of epithelial ovarian cancer via exosomal shuttling of microRNA. Cancer Letters, 2017, 393, 60-67.	7.2	77
4	Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort. BMC Infectious Diseases, 2020, 20, 629.	2.9	73
5	Toxicity and therapy of cisplatin-loaded EGF modified mPEG-PLGA-PLL nanoparticles for SKOV3 cancer in mice. Biomaterials, 2013, 34, 4068-4077.	11.4	54
6	Specific cell targeting with APRPG conjugated PEG–PLGA nanoparticles for treating ovarian cancer. Biomaterials, 2014, 35, 983-992.	11.4	49
7	Association between the vaginal microbiome and high-risk human papillomavirus infection in pregnant Chinese women. BMC Infectious Diseases, 2019, 19, 677.	2.9	49
8	Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1807-1816.	2.5	44
9	Sphingosine kinase 1/sphingosine-1-phosphate (S1P)/S1P receptor axis is involved in ovarian cancer angiogenesis. Oncotarget, 2017, 8, 74947-74961.	1.8	43
10	Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer. British Journal of Cancer, 2021, 124, 414-424.	6.4	38
11	Crosstalk between EGFR and TrkB enhances ovarian cancer cell migration and proliferation. International Journal of Oncology, 2006, 29, 1003-11.	3.3	34
12	Erlotinib overcomes paclitaxel-resistant cancer stem cells by blocking the EGFR-CREB/GRβ-IL-6 axis in MUC1-positive cervical cancer. Oncogenesis, 2019, 8, 70.	4.9	33
13	Paclitaxel and ceramide synergistically induce cell death with transient activation of EGFR and ERK pathway in pancreatic cancer cells. Oncology Reports, 2006, 16, 907-13.	2.6	33
14	Effectiveness of photodynamic therapy with 5-aminolevulinic acid on HPV clearance in women without cervical lesions. Photodiagnosis and Photodynamic Therapy, 2021, 34, 102293.	2.6	28
15	Transient activation of EGFR/AKT cell survival pathway and expression of survivin contribute to reduced sensitivity of human melanoma cells to betulinic acid. International Journal of Oncology, 2005, 27, 823-30.	3.3	22
16	The effect of local photodynamic therapy with 5-aminolevulinic acid for the treatment of cervical low-grade squamous intraepithelial lesions with high-risk HPV infection: A retrospective study. Photodiagnosis and Photodynamic Therapy, 2021, 33, 102172.	2.6	19
17	Effectiveness of photodynamic therapy in women of reproductive age with cervical high-grade squamous intraepithelial lesions (HSIL/CIN2). Photodiagnosis and Photodynamic Therapy, 2021, 36, 102517.	2.6	17
18	Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death. International Journal of Oncology, 2005, 27, 1441-8.	3.3	17

#	Article	IF	CITATIONS
19	Chinese expert consensus on the clinical applications of aminolevulinic acid-based photodynamic therapy in female lower genital tract diseases (2022). Photodiagnosis and Photodynamic Therapy, 2022, 39, 102993.	2.6	15
20	The effect of 5-Aminolaevulinic Acid Photodynamic Therapy versus CO2 laser in the Treatment of Cervical Low-grade Squamous Intraepithelial Lesions with High-Risk HPV Infection: A non-randomized, controlled pilot study. Photodiagnosis and Photodynamic Therapy, 2021, 36, 102548.	2.6	12
21	Genomic amplification of HPV, hâ€'TERC and câ€'MYC in liquidâ€'based cytological specimens for screening of cervical intraepithelial neoplasia and cancer. Oncology Letters, 2019, 17, 2099-2106.	1.8	10
22	Incidence of cervical highâ€grade squamous intraepithelial lesions and squamous cell carcinoma in women with highâ€risk human papillomavirus and normal cervical cytology: A retrospective analysis of 1858 cases stratified by age and human papillomavirus genotype. Cytopathology, 2019, 30, 419-425.	0.7	9
23	Evaluation of p16/Ki-67 Dual-Stained Cytology in Triaging HPV-Positive Women during Cervical Cancer Screening. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1246-1252.	2.5	9
24	Epidemiology and analysis of potential risk factors of highâ€risk human papillomavirus (HPV) in Shanghai China: A crossâ€sectional oneâ€year study in nonâ€vaccinated women. Journal of Medical Virology, 2022, 94, 761-770.	5.0	9
25	Female third party lymphocytes are effective for immunotherapy of patients with unexplained primary recurrent spontaneous abortion: A retrospective analysis of outcomes. European Journal of Contraception and Reproductive Health Care, 2015, 20, 428-437.	1.5	5
26	Clinical evaluation of a real-time optoelectronic device in cervical cancer screening. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 266, 182-186.	1.1	5
27	Clinical Evaluation of DNA Ploidy for the Triage of HPV-Positive Chinese Women During Cervical Cancer Screening. Cancer Prevention Research, 2021, 14, 355-362.	1.5	1
28	Paclitaxel and Ceramide synergistically induce cell death with transient activation of EGFR and ERK pathway in pancreatic cancer cells. FASEB Journal, 2006, 20, A694.	0.5	0